← Leaderboards
Melanie Rae Nicol
University Of Minnesota
$2,326,366
Attributed
$2,496,734
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $665.2K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,496,734 · 3
By mechanism
R01$1,308,986 · 1
K08$847,011 · 1
R21$340,737 · 1
Top collaborators
- Robert Lukande2 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- David R Boulware$24,302,588
- Radha Rajasingham$6,079,720
- Rebekah J. Pratt$3,831,602
- Brendan J Dougherty$2,358,063
- Jayanth Panyam$3,326,279
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsPharmaceutical PreparationsTissuesDrug ExposurePharmacologyCellsSiteFutureTrainingResearch PersonnelUgandaParticipantRegimenOralTissue BanksFormulationInvestigationCytokineDrug EfficacyLeadInflammatoryInflammationAnti-Retroviral AgentsPharmacology Study
Grant awards (10)
Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamics$453,730
R01 · FY2025 · NS · contact PI
Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamics$190,085
R01 · FY2025 · NS · contact PI
Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamics$665,171
R01 · FY2024 · NS · contact PI
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention$169,448
K08 · FY2022 · AI · contact PI
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention$169,448
K08 · FY2021 · AI · contact PI
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention$169,355
K08 · FY2020 · AI · contact PI
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention$169,392
K08 · FY2019 · AI · contact PI
Pharmacology of Antiretrovirals in Anatomical Brain Tissue among persons with chronic HIV infection$164,023
R21 · FY2019 · NS · contact PI
Pharmacology of Antiretrovirals in Anatomical Brain Tissue among persons with chronic HIV infection$176,714
R21 · FY2018 · NS · contact PI
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention$169,368
K08 · FY2018 · AI · contact PI